Royal Philips has announced the unveiling of its latest innovation in interventional oncology at the Cardiovascular and Interventional Radiological Society of Europe annual meeting (CIRSE 2016, 10-14 September, Barcelona, Spain).
Philips’ next generation interventional oncology solution OncoSuite will enable physicians to provide analysis and minimally invasive, targeted treatment of tumour lesions reducing the impact to healthy tissue. It offers clinicians a better view of the treatment targets for informed decision making. OncoSuite also features the world’s first optimised imaging for LC Bead LUMI that provides real-time visible confirmation of bead location during embolization procedures.
“While OncoSuite can be used for a number of different cancers including bone, kidney and lung, the solution and its specific tools have been optimised for the treatment of patients with liver cancer,” said Jeff Geschwind, chairman and chief of the Department of Radiology and Biomedical Imaging at the Yale School of Medicine. “Given the steady increase in the prevalence of non-alcoholic fatty liver disease and liver cancer, the development and availability of new technology is much needed to provide interventional oncologists with a breakthrough that allows best possible treatment for these patients.”
Geschwind continued: “What matters most in these cases, is the ability to visualise the liver tumours, even small ones, during the procedure and to approach them in a very targeted way to maximise the therapeutic outcome, while avoiding the destruction of healthy liver tissue. OncoSuite is designed to help us see, reach and treat liver cancer in a better way.”
OncoSuite is Philips’ integrated solution to enhance tumour embolization and ablation procedures with Philips’ interventional X-ray systems. It is the only platform in the industry that supports both procedures enabling physicians to target multiple tumour lesions simultaneously. OncoSuite comprises Philips’ innovative product offerings for enhanced imaging (XperCT Dual), live 3D image guidance for tumour embolization (EmboGuide) and live 3D image guidance for tumour ablation (XperGuide).
BTG and Philips have been working in close collaboration on the visualisation benefits of radio-opaque beads in combination with image-guided therapy. Together the companies have calibrated LC Bead LUMI and Philips Live Image Guidance Software to help interventional radiologists and multidisciplinary teams to visualise better treatment options for patients with liver cancer. As a result, the next generation OncoSuite also features the world’s first optimised imaging for LC Bead LUMI that provides real-time visible confirmation of bead location during embolization procedures. In addition, the new Wiper Movement functionality improves workflow with automatic Dual Phase imaging, helping physicians to acquire two 3D cone beam CT datasets at different times of the procedure in a single step.